Skip to main content

News

January 8, 2026

SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

January 6, 2026

SpliceBio Appoints Don Munoz as Chief Financial Officer

June 11, 2025

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

March 13, 2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

December 12, 2024

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

October 15, 2024

Splice Bio Awarded With “Torres Quevedo” Grants

April 10, 2024

SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024

January 3, 2024

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

October 17, 2023

SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

June 20, 2023

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program

January 26, 2023

Splice Bio awarded with a “Colaboración Público-Privada” grant

February 16, 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline